The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...
July 2 (Reuters) - Organon (OGN.N), opens new tab said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed ...
Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...
Rochester, Minn.-based Mayo Clinic has developed a framework that uses computer modeling and electronic health records to simulate “virtual clinical trials” for heart failure treatments. Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback